Sara Cherry, PhD, reviews ongoing research at the Penn Center for Precision Medicine to develop a personalized approach to acute myeloid leukemia that directly tests each patient’s tumor cells for sensitivity to FDA–approved and investigational drugs, matching each patient to the optimal therapy for their disease. Dr. Cherry is a Professor of Microbiology and Director of the Chemogenomic Discovery Program at Penn Medicine.
Related Links:
Personalized Diagnostics for Hematologic and Solid Tumor Cancers
Dr Cherry’s Profile
Published
February 13, 2018
Created by
BROADCASTMED